Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells

Oncotarget

Volumn 6, Issue 38, 2015, Pages 41194-41203

  Zhuang, Chengle ^a,b   Li, Jianfa ^a,b   Liu, Yuchen ^a   Chen, Mingwei ^a,c   Yuan, Jiancheng ^a   Fu, Xing ^a   Zhan, Yonghao ^a   Liu, Li ^a   Lin, Junhao ^a   Zhou, Qing ^a   Xu, Wen ^a   Zhao, Guoping ^d   Cai, Zhiming ^a   Huang, Weiren ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Bladder cancer; LncRNAs; PVT1; Synthetic biology; Tetracycline inducible

Indexed keywords

DOXYCYCLINE; LONG UNTRANSLATED RNA; SHORT HAIRPIN RNA; TETRACYCLINE; PVT1 LONG-NON-CODING RNA, HUMAN; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE FUNCTION; GENE SILENCING; GENETIC REGULATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MIDDLE AGED; ONCOGENE; PVT1 ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; SYNTHETIC BIOLOGY; UPREGULATION; BLADDER TUMOR; CANCER GRADING; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; RNA, SMALL INTERFERING; TETRACYCLINE; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84951162242     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5880     Document Type: Article

References (32)

1. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010; 60:244-272.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
3. Marta GN, Hanna SA, Gadia R, Correa SF, Silva JL, Carvalho Hde A. The role of radiotherapy in urinary bladder cancer: current status. Int Braz J Urol. 2012; 38:144-153.
4. Racioppi M, D'Agostino D, Totaro A, Pinto F, Sacco E, D'Addessi A, Marangi F, Palermo G, Bassi PF. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int. 2012; 88:249-258.
5. Batista PJ, Chang HY. Long non-coding RNAs: cellular address codes in development and disease. Cell. 2013; 152:1298-1307.
6. Geisler S, Coller J. RNA in unexpected places: long noncoding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013; 14:699-712.
7. Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154:26-46.
8. Bo H, Gong Z, Zhang W, Li X, Zeng Y, Liao Q, Chen P, Shi L, Lian Y, Jing Y, Tang K, Li Z, Zhou Y, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget. 2015; 6:20404-18.
9. Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015; 6:7899-917.
10. Bawa P, Zackaria S, Verma M, Gupta S, Srivatsan R, Chaudhary B, Srinivasan S. Integrative Analysis of Normal Long Intergenic Non-Coding RNAs in Prostate Cancer. PLoS One. 2015; 10:e0122143.
11. Liu E, Liu Z, Zhou Y. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol. 2015; 8:3803-10.
12. Ding C, Yang Z, Lv Z, Du C, Xiao H, Peng C, Cheng S, Xie H, Zhou L, Wu J, Zheng S. Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncol Lett. 2015; 9:955-963.
13. Kong R, Zhang EB, Yin DD, You LH, Xu TP, Chen WM, Xia R, Wan L, Sun M, Wang ZX, De W, Zhang ZH. Longnoncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer. 2015; 14:82.
14. Colombo T, Farina L, Macino G, Paci P. PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int. 2015; 2015:304208.
15. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007; 13:5745-55.
16. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS, et al. Regulatable Gene Expression Systems for Gene Therapy Applications: Progress and Future Challenges. Mol Ther. 2005; 12:189-211.
17. Kis Z, Pereira HS, Homma T, Pedrigi RM, Krams R. Mammalian synthetic biology: emerging medical applications. J R Soc Interface. 2015; 12.
18. Chehrehasa F, Meedeniya AC, Dwyer P, Abrahamsen G, Mackay-Sim A. EdU, a new thymidine analogue for labelling proliferating cells in the nervous system. J Neurosci Methods. 2009; 177:122-130.
19. Yu Y, Arora A, Min W, Roifman CM, Grunebaum E. EdU incorporation is an alternative non-radioactive assay to [(3)H] thymidine uptake for in vitro measurement of mice T-cell proliferations. J Immunol Methods. 2009; 350:29-35.
20. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY. Long non-coding RNA as modular scaffold of histone modification complexes. Science. 2010; 329:689-693.
21. Ponting CP, Oliver PL, Reik W. Evolution and functions of long non-coding RNAs. Cell. 2009; 136:629-641.
22. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014; 512:82-86.
23. Seo HK, Ahn KO, Jung NR, Shin JS, Park WS, Lee KH, Lee SJ, Jeong KC. Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. Oncotarget. 2014; 5:326-337.
24. Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, Yang N, Zhou WP, Li WL, Li W, Sun SH. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology. 2014; 60:1278-90.
25. Beck-Engeser GB, Lum AM, Huppi K, Caplen NJ, Wang BB, Wabl M. Pvt1-encoded microRNAs in oncogenesis. Retrovirology. 2008; 5:4.
26. Liu Y, Han Y, Huang W, Duan Y, Mou L, Jiang Z, Fa P, Xie J, Diao R, Chen Y, Ye Y, Yang R, Chen J, et al. Wholegenome synthesis and characterization of viable S13-like bacteriophages. PloS one. 2012; 7:e41124.
27. Liu Y, Zeng Y, Liu L, Zhuang C, Fu X, Huang W, Cai Z. Synthesizing AND gate genetic circuits based on CRISPRCas9 for identification of bladder cancer cells. Nat Commun. 2014; 5:5393.
28. Millis MP, Bowen D, Kingsley C, Watanabe RM, Wolford JK. Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. Diabetes. 2007; 56:3027-3032.
29. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014; 5:2318-29.
30. Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, Wang Z, Ding G, Zhuang SM, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011; 286:36677-85.
31. Guo T, Wang W, Zhang H, Liu Y, Chen P, Ma K, Zhou C. ISL1 promotes pancreatic islet cell proliferation. PLoS One. 2011; 6:e22387.
32. Zhuang CL, Fu X, Liu L, Liu YC, Huang WR, Cai ZM. Synthetic miRNA sponges driven by mutant hTERT promoter selectively inhibit the progression of bladder cancer. Tumour Biol. 2015; 36:1-7.